Paulina Selaru
Overview
Explore the profile of Paulina Selaru including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu Y, Lu S, Lu Y, Zhou J, Shi Y, Sriuranpong V, et al.
J Thorac Oncol
. 2018 Jul;
13(10):1539-1548.
PMID: 29966800
Introduction: The phase III randomized PROFILE 1014 study demonstrated superiority of crizotinib to first-line chemotherapy in prolonging progression-free survival (PFS) in previously untreated patients with ALK receptor tyrosine kinase gene...
2.
Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, et al.
Am J Hematol
. 2018 Jan;
93(5):607-614.
PMID: 29352732
Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), MET, and ROS1, is approved for treatment of patients with ALK-positive or ROS1-positive advanced non-small-cell lung cancer (NSCLC). However, ALK rearrangements are...
3.
Solomon B, Cappuzzo F, Felip E, Blackhall F, Costa D, Kim D, et al.
J Clin Oncol
. 2016 Mar;
34(24):2858-65.
PMID: 27022118
Purpose: Intracranial efficacy of first-line crizotinib versus chemotherapy was compared prospectively in the phase III PROFILE 1014 study in ALK-positive non-small-cell lung cancer. Patients And Methods: Patients were randomly assigned...
4.
Costa D, Shaw A, Ou S, Solomon B, Riely G, Ahn M, et al.
J Clin Oncol
. 2015 Jan;
33(17):1881-8.
PMID: 25624436
Purpose: Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged non-small-cell lung cancer (NSCLC). The clinical benefits of crizotinib in patients with brain metastases have not been...
5.
Pithavala Y, Chen Y, Toh M, Selaru P, LaBadie R, Garrett M, et al.
Cancer Chemother Pharmacol
. 2012 May;
70(1):103-12.
PMID: 22644797
Purpose: To evaluate the effect of food on axitinib pharmacokinetics in healthy volunteers with two different crystal polymorphs. Methods: Two separate open-label, randomized, single-dose, three-period, crossover trials were conducted. Study...
6.
Scagliotti G, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, et al.
J Clin Oncol
. 2012 May;
30(17):2070-8.
PMID: 22564989
Purpose: Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non-small-cell lung cancer (NSCLC), based on the importance of the signaling pathways involved in tumor growth,...
7.
Shaw A, Yeap B, Solomon B, Riely G, Gainor J, Engelman J, et al.
Lancet Oncol
. 2011 Sep;
12(11):1004-12.
PMID: 21933749
Background: ALK gene rearrangement defines a new molecular subtype of non-small-cell lung cancer (NSCLC). In a recent phase 1 clinical trial, the ALK tyrosine-kinase inhibitor (TKI) crizotinib showed marked antitumour...
8.
Gervais R, Hainsworth J, Blais N, Besse B, Laskin J, Hamm J, et al.
Lung Cancer
. 2011 Jun;
74(3):474-80.
PMID: 21680048
This open-label, phase II study evaluated the antitumor activity and safety of sunitinib monotherapy as maintenance treatment following first-line chemotherapy in patients with locally advanced or metastatic non-small cell lung...
9.
Pithavala Y, Tong W, Mount J, Rahavendran S, Garrett M, Hee B, et al.
Invest New Drugs
. 2010 Aug;
30(1):273-81.
PMID: 20740300
Objective: Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, is metabolized primarily by cytochrome P450 (CYP) 3A with minor contributions...
10.
Haura E, Ricart A, Larson T, Stella P, Bazhenova L, Miller V, et al.
Clin Cancer Res
. 2010 Mar;
16(8):2450-7.
PMID: 20332327
Purpose: To evaluate the efficacy of mitogen-activated protein kinase/extracellular signal-related kinase kinase inhibitor PD-0325901 in advanced non-small cell lung cancer patients who had experienced treatment failure after, or were refractory...